Paper20175274
Toxic vitreitis outbreak after intravitreal injection.
Ness T and 4 others. Retina, 2010. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Toxic vitreitis outbreak after intravitreal injection. Papers, record 20175274. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20175274
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Disease Outbreaks | Major topic |
| Eye Diseases | Major topic |
| Syringes | Major topic |
| Vitreous Body | Major topic |
| Aged | |
| Aged, 80 and over | |
| Antibodies, Monoclonal | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Female | |
| Humans | |
| Injections | |
| Macular Degeneration | |
| Macular Edema | |
| Male | |
| Ranibizumab | |
| Retinal Hemorrhage | |
| Retrospective Studies | |
| Suppuration | |
| Triamcinolone Acetonide |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 21336079 | Toxic vitreitis outbreak after intravitreal injection. | https://conductscience.org/library/papers/21336079 |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38223782 | Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee. | J Vitreoretin Dis | 2024 | https://conductscience.org/library/papers/38223782 | PubMed |
| 37197577 | Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results. | Clin Ophthalmol | 2023 | https://conductscience.org/library/papers/37197577 | PubMed |
| 35715871 | Ocular inflammation after agitation of siliconized and silicone oil-free syringes: a randomized, double-blind, controlled clinical trial. | Int J Retina Vitreous | 2022 | https://conductscience.org/library/papers/35715871 | PubMed |
| 35194509 | Toxic Intraocular Syndrome. | J Ophthalmic Vis Res | 2022 | https://conductscience.org/library/papers/35194509 | PubMed |
| 34932153 | Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. | Graefes Arch Clin Exp Ophthalmol | 2022 | https://conductscience.org/library/papers/34932153 | PubMed |
| 34604691 | Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. | J Vitreoretin Dis | 2021 | https://conductscience.org/library/papers/34604691 | PubMed |
| 33631912 | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection. | Turk J Ophthalmol | 2021 | https://conductscience.org/library/papers/33631912 | PubMed |
| 32789284 | Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. | J Vitreoretin Dis | 2020 | https://conductscience.org/library/papers/32789284 | PubMed |
| 31156880 | Assessment of bevacizumab quality and stability in repackaged syringes for clinical use. | Eur J Hosp Pharm | 2016 | https://conductscience.org/library/papers/31156880 | PubMed |
| 29802422 | [Endophthalmitis]. | Ophthalmologe | 2018 | https://conductscience.org/library/papers/29802422 | PubMed |
| 23788205 | Quality of bevacizumab compounded for intravitreal administration. | Eye (Lond) | 2013 | https://conductscience.org/library/papers/23788205 | PubMed |
| 23559321 | [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. | Ophthalmologe | 2014 | https://conductscience.org/library/papers/23559321 | PubMed |
| 23307955 | Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. | Invest Ophthalmol Vis Sci | 2013 | https://conductscience.org/library/papers/23307955 | PubMed |
| 22983424 | Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. | Angiogenesis | 2013 | https://conductscience.org/library/papers/22983424 | PubMed |
| 22048244 | Endophthalmitis following intravitreal injections. | Graefes Arch Clin Exp Ophthalmol | 2012 | https://conductscience.org/library/papers/22048244 | PubMed |
| 21705685 | Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model. | Invest Ophthalmol Vis Sci | 2011 | https://conductscience.org/library/papers/21705685 | PubMed |
| 21051703 | Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. | Invest Ophthalmol Vis Sci | 2011 | https://conductscience.org/library/papers/21051703 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20175274
GET https://conductscience.org/api/papers/v1/20175274/authors